C-Met as a potential target for the treatment of gastrointestinal cancer: Current status and future perspectives
出版年份 2017 全文链接
标题
C-Met as a potential target for the treatment of gastrointestinal cancer: Current status and future perspectives
作者
关键词
-
出版物
JOURNAL OF CELLULAR PHYSIOLOGY
Volume 232, Issue 10, Pages 2657-2673
出版商
Wiley
发表日期
2017-01-11
DOI
10.1002/jcp.25794
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Novel c-Met inhibitor suppresses the growth of c-Met-addicted gastric cancer cells
- (2016) Chi Hoon Park et al. BMC CANCER
- c-MET immunostaining in colorectal carcinoma is associated with local disease recurrence
- (2015) Jaudah Al-Maghrabi et al. BMC CANCER
- Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer model
- (2015) Franziska Brandes et al. BMC CANCER
- Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients
- (2015) Nozomu Fuse et al. Gastric Cancer
- Multimodal treatment of gastric cancer in the west: Where are we going?
- (2015) Daniele Marrelli WORLD JOURNAL OF GASTROENTEROLOGY
- HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma
- (2014) Y J Liu et al. BRITISH JOURNAL OF CANCER
- Abstract 3371: Preclinical disposition and pharmacokinetics of volitinib, a novel selective cMet inhibitor .
- (2014) Yi Gu et al. CANCER RESEARCH
- Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer
- (2014) E. Van Cutsem et al. CLINICAL CANCER RESEARCH
- Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination with Bevacizumab in Patients with Advanced Solid Malignancies
- (2014) R. Salgia et al. CLINICAL CANCER RESEARCH
- Targeting c-MET/HGF Signaling Pathway in Upper Gastrointestinal Cancers: Rationale and Progress
- (2014) Sharareh Gholamin et al. CURRENT DRUG TARGETS
- Synergistic Activity of the c-Met and Tubulin Inhibitor Tivantinib (ARQ197) with Pemetrexed in Mesothelioma Cells
- (2014) Leticia Leon et al. CURRENT DRUG TARGETS
- MET As a Potential Target for the Treatment of Upper Gastrointestinal Cancers: Characterization of Novel c-Met Inhibitors from Bench to Bedside
- (2014) A. Avan et al. CURRENT MEDICINAL CHEMISTRY
- Overexpression of CMET is associated with signal transducer and activator of transcription 3 activation and diminished prognosis in oesophageal adenocarcinoma but not in squamous cell carcinoma
- (2014) Ildiko Mesteri et al. EUROPEAN JOURNAL OF CANCER
- Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study
- (2014) Timothy Iveson et al. LANCET ONCOLOGY
- Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and growth in c-MET amplified gastric cancer patient-derived tumor xenograft models
- (2014) Paul R. Gavine et al. Molecular Oncology
- Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines
- (2014) Antonio Calles et al. Molecular Oncology
- c-Met signaling in the development of tumorigenesis and chemoresistance: Potential applications in pancreatic cancer
- (2014) Daniel Delitto WORLD JOURNAL OF GASTROENTEROLOGY
- The c-Met Inhibitor MSC2156119J Effectively Inhibits Tumor Growth in Liver Cancer Models
- (2014) Friedhelm Bladt et al. Cancers
- A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis
- (2013) A Santoro et al. BRITISH JOURNAL OF CANCER
- Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met-driven Pancreatic Carcinoma
- (2013) A. Avan et al. CANCER RESEARCH
- EMD 1214063 and EMD 1204831 Constitute a New Class of Potent and Highly Selective c-Met Inhibitors
- (2013) F. Bladt et al. CLINICAL CANCER RESEARCH
- Targeting the MET gene for the treatment of non-small-cell lung cancer
- (2013) F. Gelsomino et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer
- (2013) Yoon-Koo Kang et al. INVESTIGATIONAL NEW DRUGS
- Hepatocellular Carcinoma
- (2013) Kisha A. Mitchell JOURNAL OF CLINICAL GASTROENTEROLOGY
- MET As a Possible Target for Non–Small-Cell Lung Cancer
- (2013) Ahad A. Sadiq et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer
- (2013) Manish A. Shah et al. PLoS One
- Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent
- (2013) M. Merchant et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Lentivirus-mediated RNA silencing of c-Met markedly suppresses peritoneal dissemination of gastric cancer in vitro and in vivo
- (2012) Xiao-lei Wang et al. ACTA PHARMACOLOGICA SINICA
- Cellular and molecular mechanisms of hepatocellular carcinoma: an update
- (2012) Rajagopal N. Aravalli et al. ARCHIVES OF TOXICOLOGY
- MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome
- (2012) H E Lee et al. BRITISH JOURNAL OF CANCER
- Abstract 3612: A novel and selective c-Met inhibitor against subcutaneous xenograft and othotopic brain tumor models
- (2012) Yumin Cui et al. CANCER RESEARCH
- Met Kinase Inhibitor E7050 Reverses Three Different Mechanisms of Hepatocyte Growth Factor-Induced Tyrosine Kinase Inhibitor Resistance in EGFR Mutant Lung Cancer
- (2012) W. Wang et al. CLINICAL CANCER RESEARCH
- Enhancement of the Antiproliferative Activity of Gemcitabine by Modulation of c-Met Pathway in Pancreatic Cancer
- (2012) Amir Avan et al. CURRENT PHARMACEUTICAL DESIGN
- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Current Status and Future Perspectives in the Development of Novel Irreversible Inhibitors for the Treatment of Mutant Non-small Cell Lung Cancer
- (2012) Elena Galvani et al. CURRENT PHARMACEUTICAL DESIGN
- Loss of HGF/c-Met Signaling in Pancreatic β-Cells Leads to Incomplete Maternal β-Cell Adaptation and Gestational Diabetes Mellitus
- (2012) Cem Demirci et al. DIABETES
- Hepatocyte Growth Factor Plays a Key Role in Insulin Resistance-Associated Compensatory Mechanisms
- (2012) Tiago G. Araújo et al. ENDOCRINOLOGY
- Response to Crizotinib inROS1-Rearranged Non–Small-Cell Lung Cancer
- (2012) Takefumi Komiya et al. JOURNAL OF CLINICAL ONCOLOGY
- Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
- (2012) Armando Santoro et al. LANCET ONCOLOGY
- MET Activation Mediates Resistance to Lapatinib Inhibition of HER2-Amplified Gastric Cancer Cells
- (2012) C.-T. Chen et al. MOLECULAR CANCER THERAPEUTICS
- Antitumor Action of the MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) in Gastric Cancer Positive for MET Amplification
- (2012) W. Okamoto et al. MOLECULAR CANCER THERAPEUTICS
- Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia
- (2012) Alex Kentsis et al. NATURE MEDICINE
- Microenvironment Elements Involved in the Development of Pancreatic Cancer Tumor
- (2012) Katarzyna Gardian et al. Gastroenterology Research and Practice
- Suppression of Tumor Invasion and Metastasis by Concurrent Inhibition of c-Met and VEGF Signaling in Pancreatic Neuroendocrine Tumors
- (2012) Barbara Sennino et al. Cancer Discovery
- Multiple Mutations and Bypass Mechanisms Can Contribute to Development of Acquired Resistance to MET Inhibitors
- (2011) J. Qi et al. CANCER RESEARCH
- c-Met Is a Marker of Pancreatic Cancer Stem Cells and Therapeutic Target
- (2011) Chenwei Li et al. GASTROENTEROLOGY
- Discovery of a Novel Mode of Protein Kinase Inhibition Characterized by the Mechanism of Inhibition of Human Mesenchymal-epithelial Transition Factor (c-Met) Protein Autophosphorylation by ARQ 197
- (2011) Sudharshan Eathiraj et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Genetic Activation of theMETPathway and Prognosis of Patients With High-Risk, Radically Resected Gastric Cancer
- (2011) Francesco Graziano et al. JOURNAL OF CLINICAL ONCOLOGY
- METAmplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib
- (2011) Jochen K. Lennerz et al. JOURNAL OF CLINICAL ONCOLOGY
- 665 A PHASE I/II STUDY OF FORETINIB, AN ORAL MULTIKINASE INHIBITOR TARGETING MET, RON, AXL, TIE-2 AND VEGFR IN ADVANCED HEPATOCELLULAR CARCINOMA (HCC)
- (2011) T. Yau et al. JOURNAL OF HEPATOLOGY
- Induction of MET by Ionizing Radiation and Its Role in Radioresistance and Invasive Growth of Cancer
- (2011) Francesca De Bacco et al. JNCI-Journal of the National Cancer Institute
- Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification
- (2011) Sai-Hong Ignatius Ou et al. Journal of Thoracic Oncology
- HCC and angiogenesis: possible targets and future directions
- (2011) Andrew X. Zhu et al. Nature Reviews Clinical Oncology
- Hepatocellular Carcinoma
- (2011) Hashem B. El-Serag NEW ENGLAND JOURNAL OF MEDICINE
- Silencing of RON Receptor Signaling Promotes Apoptosis and Gemcitabine Sensitivity in Pancreatic Cancers
- (2010) J. Logan-Collins et al. CANCER RESEARCH
- MET and KRAS Gene Amplification Mediates Acquired Resistance to MET Tyrosine Kinase Inhibitors
- (2010) V. Cepero et al. CANCER RESEARCH
- Disruption of Hepatocyte Growth Factor/c-Met Signaling Enhances Pancreatic -Cell Death and Accelerates the Onset of Diabetes
- (2010) J. Mellado-Gil et al. DIABETES
- Expression and Prognostic Significance of CD151, c-Met, and Integrin alpha3/alpha6 in Pancreatic Ductal Adenocarcinoma
- (2010) Guang-Hui Zhu et al. DIGESTIVE DISEASES AND SCIENCES
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- TAK-701, a Humanized Monoclonal Antibody to Hepatocyte Growth Factor, Reverses Gefitinib Resistance Induced by Tumor-Derived HGF in Non-Small Cell Lung Cancer with an EGFR Mutation
- (2010) W. Okamoto et al. MOLECULAR CANCER THERAPEUTICS
- ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity
- (2010) N. Munshi et al. MOLECULAR CANCER THERAPEUTICS
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
- (2010) Juan Valle et al. NEW ENGLAND JOURNAL OF MEDICINE
- Descriptive epidemiology of cholangiocarcinoma in Italy
- (2009) Domenico Alvaro et al. DIGESTIVE AND LIVER DISEASE
- PAX6 Is Expressed in Pancreatic Cancer and Actively Participates in Cancer Progression through Activation of the MET Tyrosine Kinase Receptor Gene
- (2009) Joseph B. Mascarenhas et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Therapeutic potential of hepatocyte growth factor/scatter factor neutralizing antibodies: Inhibition of tumor growth in both autocrine and paracrine hepatocyte growth factor/scatter factor:c-Met-driven models of leiomyosarcoma
- (2009) C.-F. Gao et al. MOLECULAR CANCER THERAPEUTICS
- Developing c-MET pathway inhibitors for cancer therapy: progress and challenges
- (2009) Xiangdong Liu et al. TRENDS IN MOLECULAR MEDICINE
- The Met tyrosine kinase receptor in development and cancer
- (2008) Alessandra Gentile et al. CANCER AND METASTASIS REVIEWS
- c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases
- (2008) Zhao-Shi Zeng et al. CANCER LETTERS
- MET receptor tyrosine kinase as a therapeutic anticancer target
- (2008) Christine M. Stellrecht et al. CANCER LETTERS
- MetMAb, the One-Armed 5D5 Anti-c-Met Antibody, Inhibits Orthotopic Pancreatic Tumor Growth and Improves Survival
- (2008) H. Jin et al. CANCER RESEARCH
- The Prognostic Significance of RON and MET Receptor Coexpression in Patients with Colorectal Cancer
- (2008) Chung-Ta Lee et al. DISEASES OF THE COLON & RECTUM
- Expression and mutational analysis ofMETin human solid cancers
- (2008) Patrick C. Ma et al. GENES CHROMOSOMES & CANCER
- Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma
- (2008) Ai-Wu Ke et al. HEPATOLOGY
- Drug development of MET inhibitors: targeting oncogene addiction and expedience
- (2008) Paolo M. Comoglio et al. NATURE REVIEWS DRUG DISCOVERY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now